Stereotaxis (STXS) 10-K 16 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 29, 2020	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 112,400,000
Entity Common Stock, Shares Outstanding		69,033,391
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 30,182,115	$ 10,796,072
Accounts receivable, net of allowance of $380,212 and $398,847 in 2019 and 2018, respectively	5,329,577	5,021,111
Inventories, net	1,847,530	1,191,666
Prepaid expenses and other current assets	1,470,922	963,700
Total current assets	38,830,144	17,972,549
Property and equipment, net	250,443	343,693
Operating lease right-of-use assets	4,286,064
Other assets	218,103	198,365
Total assets	43,584,754	18,514,607
Current liabilities:
Accounts payable	2,099,097	1,726,360
Accrued liabilities	2,721,104	2,642,481
Deferred revenue	5,092,455	5,825,536
Current portion of operating lease liabilities	2,248,189
Total current liabilities	12,160,845	10,194,377
Long-term deferred revenue	554,258	407,151
Operating lease liabilities	2,089,537
Other liabilities	255,517	641,461
Total liabilities	15,060,157	11,242,989
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 23,110 and 23,900 shares outstanding at 2019 and 2018, respectively	5,758,190	5,960,475
Stockholders' equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 and no shares outstanding at 2019 and 2018, respectively	5,610
Common stock, par value $0.001; 300,000,000 shares authorized, 68,529,623 and 59,058,297 shares issued at 2019 and 2018, respectively	68,530	59,058
Additional paid in capital	504,211,040	478,179,574
Treasury stock, 4,015 shares at 2019 and 2018	(205,999)	(205,999)
Accumulated deficit	(481,312,774)	(476,721,490)
Total stockholders' equity	22,766,407	1,311,143
Total liabilities and stockholders' equity	$ 43,584,754	$ 18,514,607

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 380,212	$ 398,847
Series A Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Series A Convertible Preferred Stock, shares outstanding	23,110	23,900
Series B Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Series B Convertible Preferred Stock, shares authorized	10,000,000	10,000,000
Series B Convertible Preferred Stock, shares outstanding	5,610,121
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	68,529,623	59,058,297
Treasury stock, shares	4,015	4,015

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Sublease	$ 986,123
Total revenue	28,902,550	$ 29,346,617
Cost of revenue:
Sublease	986,122
Total cost of revenue	6,136,459	5,717,179
Gross margin	22,766,091	23,629,438
Operating expenses:
Research and development	9,021,403	8,219,387
Sales and marketing	12,733,389	12,965,920
General and administrative	5,838,158	4,901,170
Total operating expenses	27,592,950	26,086,477
Operating loss	(4,826,859)	(2,457,039)
Other income		2,590,361
Interest income (expense)	235,575	(16,566)
Net income (loss)	(4,591,284)	116,756
Cumulative dividend on convertible preferred stock	(1,429,400)	(1,434,000)
Loss attributable to common stockholders	$ (6,020,684)	$ (1,317,244)
Net loss per share attributable to common stockholders:
Basic	$ (0.10)	$ (0.03)
Diluted	$ (0.10)	$ (0.03)
Weighted average number of common shares and equivalents:
Basic	63,051,581	52,082,618
Diluted	63,051,581	52,082,618
Systems [Member]
Revenue:
Total revenue	$ 2,066,253	$ 1,582,053
Cost of revenue:
Total cost of revenue	1,411,423	1,788,658
Disposables, Service and Accessories [Member]
Revenue:
Total revenue	25,850,174	27,764,564
Cost of revenue:
Total cost of revenue	$ 3,738,914	$ 3,928,521

Statements of Convertible Prefe

Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)		Convertible Preferred Stock Series A (Mezzanine) [Member]	Convertible Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2017		$ 5,960,475		$ 22,806	$ 450,748,403	$ (205,999)	$ (477,132,808)	$ (26,567,598)
Beginning Balance, Shares at Dec. 31, 2017		23,900		22,805,731
Issuance of common stock and warrants				$ 35,793	26,813,524			26,849,317
Issuance of common stock and warrants, Shares				35,792,593
Share-based compensation					561,115			561,115
Restricted stock vesting				$ 385	(385)			0
Restricted stock vesting, shares				385,606
Components of net income (loss)							116,756	116,756
Employee stock purchase plan				$ 74	56,917			56,991
Employee stock purchase plan, Shares				74,367
Cumulative catchup for adoption of ASC 606	[1]						294,562	294,562
Ending Balance at Dec. 31, 2018		$ 5,960,475		$ 59,058	478,179,574	$ (205,999)	(476,721,490)	1,311,143
Ending Balance, Shares at Dec. 31, 2018		23,900		59,058,297
Issuance of common stock and warrants				$ 7,779	13,312,405			13,320,184
Issuance of common stock and warrants, Shares				7,778,806
Share-based compensation				$ 207	1,811,877			1,812,084
Share-based compensation, shares				207,212
Components of net income (loss)							$ (4,591,284)	(4,591,284)
Employee stock purchase plan				$ 40	80,017			80,057
Employee stock purchase plan, Shares				39,648
Preferred stock issuance			$ 5,610		10,626,328			10,631,938
Preferred stock issuance, shares			5,610,121
Preferred stock conversion		$ (202,285)		$ 1,446	$ 200,839			$ 202,285
Preferred stock conversion, shares		(790)		1,445,660
Ending Balance at Dec. 31, 2019		$ 5,758,190	$ 5,610	$ 68,530	$ 504,211,040	$ (205,999)	$ (481,312,774)	$ 22,766,407
Ending Balance, Shares at Dec. 31, 2019		23,110	5,610,121	68,529,623
[1]	Represents the adjustments related to the adoption of new accounting standards. See Note 2 for details.

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net income (loss)	$ (4,591,284)	$ 116,756
Adjustments to reconcile net income (loss) to cash used in operating activities:
Depreciation	122,736	513,029
Amortization of intangibles		65,988
Amortization of deferred finance costs		24,657
Non-cash lease expense	2,342,344
Share-based compensation	1,330,195	560,973
Net impairment and loss on asset disposal		94,931
Adjustment of warrants		(2,590,361)
Provision for obsolete inventory		320,447
Changes in operating assets and liabilities:
Accounts receivable	(308,466)	(733,856)
Inventories	(655,864)	(365,142)
Prepaid expenses and other current assets	(507,222)	(124,419)
Other assets	(19,738)	26,775
Accounts payable	372,737	72,259
Accrued liabilities	560,482	(552,766)
Deferred revenue	(585,974)	(81,945)
Operating lease liability	(2,290,682)
Other liabilities	(385,944)	106,092
Net cash used in operating activities	(4,616,680)	(2,546,582)
Cash flows from investing activities
Purchase of fixed assets	(29,486)	(265,482)
Net cash used in investing activities	(29,486)	(265,482)
Cash flows from financing activities
Proceeds from issuance of stock, net of issuance costs	24,032,209	57,137
Proceeds from warrant exercise		9,864,697
Net cash provided by financing activities	24,032,209	9,921,834
Net increase in cash and cash equivalents	19,386,043	7,109,770
Cash and cash equivalents at beginning of period	10,796,072	3,686,302
Cash and cash equivalents at end of period	30,182,115	10,796,072
Supplemental disclosures of cash flow information:
Interest Paid

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Stereotaxis designs, manufactures and markets an advanced robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias by enabling enhanced safety, efficiency, and efficacy for catheter-based, or interventional, procedures. Our primary products include the Genesis RMN Niobe Odyssey The Genesis RMN Niobe Niobe In addition to the robotic magnetic navigation systems and their components, Stereotaxis also has developed the Odyssey Odyssey Cinema Odyssey We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. We have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Genesis RMN Niobe Odyssey Cardiodrive Vdrive Vdrive Duo V-CAS V-Loop V-Sono V-CAS Deflect We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue and efforts are ongoing to ensure the availability of integrated next generation systems and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2019 or 2018. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). As of December 31, 2019 and December 31, 2018 the Company did not have any financial assets or liabilities valued at fair value on a recurring basis. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses, freight, handling costs and wasted material attributable to abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred. Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue Revenue Recognition The Company adopted Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates as necessary. Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented 7% and 5% of revenue for the years ended December 31, 2019 and 2018, respectively. Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 33% of revenue for the years ended December 31, 2019 and 2018, respectively. Royalty: The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% of revenue for the years ended December 31, 2019 and 2018. Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for one year following installation. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 47% and 52% of revenue for the years ended December 31, 2019 and 2018, respectively. Sublease Revenue: The adoption of new lease accounting guidance as of January 1, 2019 requires the Company to record sublease income as revenue beginning in 2019. Sublease revenue represented 3% of revenue for the year ended December 31, 2019. Year Ended December 31, 2019 2018 Systems $ 2,066,253 $ 1,582,053 Disposables, service and accessories 25,850,174 27,764,564 Sublease 986,123 - Total revenue $ 28,902,550 $ 29,346,617 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $1.1 million as of December 31, 2019. Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract. The following information summarizes the Company’s contract assets and liabilities: December 31, 2019 December 31, 2018 Contract Assets - Unbilled Receivables $ 168,445 $ 251,867 Customer deposits - 487,086 Product shipped, revenue deferred 674,324 645,199 Deferred service and license fees 4,972,389 5,100,402 Total deferred revenue 5,646,713 6,232,687 Less: Long-term deferred revenue (554,258 ) (407,151 ) Total current deferred revenue $ 5,092,455 $ 5,825,536 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2019 and 2018, that was included in the deferred revenue balance at the beginning of each reporting period was $5.6 million and $5.5 million, respectively. The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets, in the Company’s balance sheet was $0.3 million as of December 31, 2019 and December 31, 2018. The Company did not incur any impairment losses during any of the periods presented. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2019 or 2018 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is re-measured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory. Net Earnings (Loss) per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2019, the Company had 1,857,599 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $2.22 per share, 46,155 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.70 per share, 42,497,068 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock, and 5,610,121 shares of our common stock issuable upon conversion of our Series B Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2019. Income Taxes In accordance with general accounting principles for income taxes , Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. Revenue from Biosense Webster Inc. related to royalties and Odyssey Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recently Issued Accounting Pronouncements Effective January 1, 2019, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05. The standard modifies the measurement approach for credit losses on financial instruments, including trade receivables, from an incurred loss method to a current expected credit loss method, otherwise known as “CECL.” The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years; early adoption is permitted. The standard must be adopted by applying a cumulative adjustment to retained earnings. The Company anticipates adopting the standard in the first quarter of 2020, although it does not expect a significant impact to the Company’s financial results. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” as part of its effort to reduce the complexity of accounting standards. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial results.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory consists of the following: December 31, 2019 December 31, 2018 Raw materials $ 3,063,532 $ 2,686,870 Work in process 515,262 2,594 Finished goods 2,164,187 2,963,013 Reserve for obsolescence (3,895,451 ) (4,460,811 ) Total inventory $ 1,847,530 $ 1,191,666

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, 2019 December 31, 2018 Prepaid expenses $ 640,252 $ 401,972 Prepaid commissions 336,594 304,585 Deposits 712,179 455,508 Total prepaid expenses and other assets 1,689,025 1,162,065 Less: Noncurrent prepaid expenses and other assets (218,103 ) (198,365 ) Total current prepaid expenses and other assets $ 1,470,922 $ 963,700

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment consist of the following: December 31, 2019 December 31, 2018 Equipment $ 6,485,873 $ 6,739,939 Leasehold improvements 2,338,441 2,684,065 8,824,314 9,424,004 Less: Accumulated depreciation (8,573,871 ) (9,080,311 ) Net property and equipment $ 250,443 $ 343,693 Certain prior year amounts have been reclassified to conform to the 2019 presentation.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets The Company’s intangible assets were fully amortized as of December 31, 2018. Amortization expense was $65,988 for the year ended December 31, 2018, as determined under the straight-line method. For the year ended December 31, 2018, the Company also recognized impairment charges of $93,482 in research and development expense related to certain intellectual property rights. The impairment is the result of an analysis that indicated it was probable the undiscounted cash flows derived from the intellectual property would not exceed its book value during its remaining useful life.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following: December 31, 2019 December 31, 2018 Accrued salaries, bonus, and benefits $ 1,421,150 $ 1,491,844 Accrued licenses and maintenance fees 483,879 577,389 Accrued warranties 141,697 149,464 Accrued taxes 206,232 192,268 Accrued professional services 383,342 489,017 Other 340,321 383,960 Total accrued liabilities 2,976,621 3,283,942 Less: Long term accrued liabilities (255,517 ) (641,461 ) Total current accrued liabilities $ 2,721,104 $ 2,642,481 Certain prior year amounts have been reclassified to conform to the 2019 presentation.

Long-Term Debt and Credit Facil

Long-Term Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt and Credit Facilities	8. Long-Term Debt and Credit Facilities As of December 31, 2019 and 2018, there were no contractual principal maturities of debt. Revolving line of credit The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The working capital line of credit matures on June 30, 2020. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $5.0 million subject to the value of collateralized assets and the interest rate is equal to the prime rate subject to a floor of 4.5%. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to April 25, 2019. The maximum availability under the revolving line of credit remains at $5.0 million, and provides for an interest rate during a “streamline period” equal to the prime rate subject to a floor of 4.5%. A “streamline period” occurs when the Company has, for each consecutive day in the immediately preceding monthly period, maintained a liquidity ratio greater than 1.75:1.00, and continuing so long as the streamline period has been maintained. Upon the termination of a streamline period, the Company must maintain the streamline threshold each consecutive day for one fiscal quarter, prior to entering into a subsequent streamline period. During non-streamline periods, the interest rate is the prime rate plus 1.5%, subject to a floor of 4.5%. In addition, the amendment requires that the liquidity ratio shall at all times include not less than $1.5 million of the Borrower’s unrestricted cash and cash equivalents maintained at the Bank prior to giving effect to any advance. On June 27, 2019, the Company entered into a Second Amendment to and Reinstatement of Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to June 30, 2020 under substantially identical terms to the prior agreement. As of December 31, 2019 and December 31, 2018, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2019 the Company had a borrowing capacity of $3.6 million based on the Company’s collateralized assets. The Company’s total liquidity as of December 31, 2019, was $33.8 million, which included cash and cash equivalents of $ million.

Lease Obligations

Lease Obligations	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Lease Obligations	9. Lease Obligations A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. On January 1, 2019, the Company adopted ASU No. 2016-02 “Leases” (Topic 842) The Company leases its facilities under operating leases, which were previously not recognized on the Company’s balance sheets. With the adoption of ASC 842, operating lease agreements are required to be recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. A portion of our principal executive office is subleased to a third party through 2021. The sublease does not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. In addition, the sublease does not contain contingent rent provisions nor are there options to extend or terminate the sublease. The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e. leases with initial terms of twelve months or less) on the balance sheet. The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception. At December 31, 2019, the weighted average discount rate for operating leases was 9% and the weighted average remaining lease term for operating lease term is 2.0 years. The following table represents lease costs and other lease information. Year Ended December 31, 2019 Operating lease cost $ 2,342,344 Short-term lease cost 77,185 Sublease income (986,123 ) Total lease cost $ 1,433,406 Cash paid within operating cash flows $ 2,458,606 The initial recognition of the right of use assets was $6.2 million. Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and equipment which are paid based on actual costs incurred. The future minimum lease payments under non-cancelable leases as of December 31, 2019 are as follows (excluding any potential sublease income): December 31, 2019 2020 $ 2,339,810 2021 2,382,661 2022 and thereafter - Total lease payments $ 4,722,471 Less: Interest (384,745 ) Present value of lease liabilities $ 4,337,726 The undiscounted future cash flows to be received under the sublease are $1.0 million in 2020 and 2021.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Convertible Preferred Stock and Stockholders' Equity	10. Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2019. 2019 Equity Financing and Series B Convertible Preferred Stock On August 7, 2019, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors, whereby it, in a private placement, agreed to issue and sell to the investors an aggregate of 6,585,000 shares of the Company’s common stock, $0.001 par value per share, at a price of $2.05 per share and 5,610,121 shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value per share which are convertible into shares of the Company’s Common Stock, at a price of $2.05 per share. The Series B Preferred Stock, which is a Common Stock equivalent but non-voting and with a blocker on conversion if the holder would exceed a specified threshold of voting security ownership, is convertible into Common Stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like as provided in the Purchase Agreement. The Series B Convertible Preferred Stock is reported in the stockholders’ equity section of the balance sheet. The Company received net proceeds of approximately $23.1 million, after offering expenses. The Company plans to use the funds for general corporate purposes Series A Convertible Preferred Stock and Warrants In September 2016, the Company issued 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock at an initial conversion rate of $0.65 per share and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent (6%) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets, or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a defined change of control. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution, and winding up of the Company. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet. The warrants issued in conjunction with the Series A Convertible Preferred Stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. Prior to their modification in February 2018, the warrants were puttable upon the occurrence of certain events outside of the Company’s control, and were classified as liabilities under ASC 480-10. The calculated fair value of the warrants was periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. The warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $0.70 per share to $0.28 per share for a period between March 1, 2018 and March 5, 2018. Any holder who exercised warrants at the reduced strike price was required to enter into a lock-up agreement with the Company agreeing not to sell the warrants or the common shares received upon exercise of the warrants for a period of 18 months following March 12, 2018. Additionally, the beneficial ownership limitation related to the warrants was modified and the right of holders to require the Company to redeem their SPA Warrants in exchange for cash in certain circumstances was eliminated. Following these modifications, the warrants were no longer subject to liability accounting and were reclassified to equity. During the restricted exercise period, Stereotaxis received exercise notices for 35,791,927 warrants and received an aggregate of $10.0 million in cash from the warrant exercise. As a result of these transactions, total stockholders’ equity increased by $27 million and common shares outstanding increased by 35,791,927 shares. The Consent and Amendment and the Amended and Restated Form of Warrants are available in a Form 8-K filed with the Securities and Exchange Commission on March 6, 2018. The Company has reserved shares of common stock for conversion of convertible preferred stock, exercise of warrants, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: December 31, 2019 December 31, 2018 Warrants 46,155 1,131,151 Series A Convertible Preferred Stock 46,398,904 47,844,562 Series B Convertible Preferred Stock 5,610,121 - Stock award plans 3,216,028 4,438,503 Employee Stock Purchase Plan 261,603 51,251 55,532,811 53,465,467 Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In July 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012. The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights. Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors. Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of equity awards to new directors generally vest over a two year period. Annual grants to directors generally vest between one and five years following grant. A summary of the option and stock appreciation rights activity for the year ended December 31, 2019 is as follows: Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2018 1,165,086 $0.74 - $43.90 $ 2.54 Granted 1,027,000 $2.03 - $4.48 $ 2.12 Exercised (134,313 ) $0.74 - $2.15 $ 1.17 Forfeited (200,174 ) $0.74 - $43.90 $ 4.29 Outstanding, December 31, 2019 1,857,599 $0.74 - $36.20 $ 2.22 As of December 31, 2019, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 8.18 years. Of the 1,857,599 options and stock appreciation rights that were outstanding as of December 31, 2019, 523,982 were vested and exercisable with a weighted average exercise price of $3.54 per share and a weighted average remaining term of 6.35 years. A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Year Ended December 31, 2019 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $0.00 - $1.00 656,444 8.17 $ 0.74 265,366 $ 0.74 $1.01 - $2.00 96,333 6.78 $ 1.50 62,794 $ 1.73 $2.01- $4.00 957,477 8.83 $ 2.05 83,477 $ 2.15 $4.01 - $10.00 117,500 5.94 $ 4.17 82,500 $ 4.04 $10.01 - $20.00 - - $ - - $ - $30.01 - $40.00 29,845 0.91 $ 34.73 29,845 $ 34.73 1,857,599 8.18 $ 2.22 523,982 $ 3.54 The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money at December 31, 2019. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2019 was approximately $6.6 million based on a closing share price of $5.29 on December 31, 2019. There were 494,137 fully vested options or stock appreciation rights outstanding at December 31, 2019 with an exercise price less than the closing stock price on December 31, 2019. During the year ended December 31, 2019 the aggregate intrinsic value of options and stock appreciation rights exercised under the Company’s stock option plans was $0.4 million. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2018 was approximately $0.3 million based on a closing share price of $1.08 on December 31, 2018. There were no fully vested options or stock appreciation rights outstanding at December 31, 2018 with an exercise price less than the closing stock price on December 31, 2018. During the year ended December 31, 2018 the aggregate intrinsic value of options and stock appreciation rights exercised under the Company’s stock option plans was less than $0.1 million. The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2019 and 2018 was $2.12 per share and $0.76 per share, respectively. A summary of the restricted stock unit activity for the year ended December 31, 2019 is as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2018 647,649 $ 0.83 Granted 420,000 $ 1.98 Vested (207,212 ) $ 1.36 Forfeited (19,725 ) $ 0.74 Outstanding, December 31, 2019 840,712 $ 1.28 The intrinsic value of restricted stock units outstanding at December 31, 2019 was $4.4 million based on a closing share price of $5.29 as of December 31, 2019. During the year ended December 31, 2019, the aggregate intrinsic value of restricted stock units vested was $0.3 million determined at the date of vesting. As of December 31, 2019, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.6 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods. 2009 Employee Stock Purchase Plan In 2009, the Company adopted its 2009 Employee Stock Purchase Plan (“ESPP”). In June 2014 and again in May 2019, our shareholders approved an amendment of the ESPP to increase the number of shares authorized for issuance under the ESPP by 250,000 shares. Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 2019, there were 261,603 remaining shares available for issuance under the Employee Stock Purchase Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The provision for income taxes consists of the following: Year Ended December 31, 2019 2018 Deferred: Federal $ (827,984 ) $ (236,779 ) State and local (41,740 ) (238,946 ) (869,724 ) (475,725 ) Valuation allowance 869,724 475,725 $ — $ — The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Year Ended December 31, 2019 2018 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.8 % (42.8 )% Permanent differences between book and tax (3.3 )% (390.5 )% Deferred tax adjustments 0.0 % 293.5 % State rate adjustments (0.9 )% (292.9 )% Prior year return-to-provision adjustment 0.3 % 4.3 % Valuation allowance (18.9 )% 407.4 % Effective income tax rate — % — % Included in permanent differences between book and tax in the above table are the differences such as nondeductible meals and entertainment and stock compensation shortfalls. In 2018, the permanent differences also included the impacts of non-deductible mark-to-market activity associated with convertible debt and warrants. The deferred state rate adjustments are a result of changes in apportionment and various state rate law changes. The deferred tax adjustments for 2018 are primarily attributable to the write-off of deferred tax assets associated with unexercised stock compensation awards that expired during the year. The components of the deferred tax asset are as follows: December 31, 2019 2018 Current accruals $ 1,660,817 $ 1,746,094 Operating lease liabilities 1,021,891 - Deferred revenue 2,749 605 Depreciation and amortization 1,095,119 1,279,973 Deferred compensation 576,269 471,143 Net operating loss carryovers 23,960,965 22,933,668 Deferred tax assets 28,317,810 26,431,483 Valuation allowance (27,228,805 ) (26,359,083 ) Net deferred tax assets before deferred tax liabilities 1,089,005 72,400 Operating lease right-of-use assets (1,009,721 ) — Capitalized compensation costs (79,284 ) (72,400 ) Net deferred tax assets $ — $ — Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. As of December 31, 2019, we had gross federal net operating loss carryforwards of approximately $104.8 million. The federal net operating loss carryforwards reflect accumulated book losses reduced for the 2013 IRC Section 382 ownership change limitation of $279.8 million and approximately $96.9 million of book/tax differences and expiration of unused carryforwards. The federal net operating loss carryforwards generated prior to the 2018 tax year will expire between 2030 and 2037. The federal net operating loss generated during 2018 and 2019 will be carried forward indefinitely as a result of changes in the tax law following the Tax Cuts and Jobs Act. As of December 31, 2019, we had state net operating loss deferred tax assets of approximately $2.0 million which will expire at various dates between 2020 and 2039 if not utilized. The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 2000 forward, all tax years from 2000 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less. At December 31, 2019 and 2018, the Company had less than $0.1 million in reserves for uncertain tax positions. The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2019, accrued interest and penalties were less than $0.1 million.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2019
Net loss per share attributable to common stockholders:
Net Loss Per Share	12. Net Loss per Share The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations: Year Ended December 31, 2019 2018 Net income (loss) $ (4,591,284 ) $ 116,756 Cumulative dividend on convertible preferred stock (1,429,400 ) (1,434,000 ) Net loss attributable to common stockholders $ (6,020,684 ) $ (1,317,244 ) Weighted average number of common shares and equivalents: 63,051,581 52,082,618 Basic EPS $ (0.10 ) $ (0.03 ) Diluted EPS $ (0.10 ) $ (0.03 ) The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: December 31, 2019 2018 Shares issuable upon vesting/exercise of: Options to purchase common stock 1,857,599 1,165,086 Series A Convertible Preferred Stock and Accumulated Dividends 42,497,068 41,743,654 Series B Convertible Preferred Stock 5,610,121 - Restricted stock units 840,712 647,649 Warrants 46,155 1,131,151 50,851,655 44,687,540

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefit Plan	13. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan. The Company recognized expense of approximately $0.2 million for the years ended December 31, 2019 and 2018. The Company matches employee contributions up to 3% of each participating employee’s salary.

Product Warranty Provisions

Product Warranty Provisions	12 Months Ended
	Dec. 31, 2019
Product Warranties Disclosures [Abstract]
Product Warranty Provisions	14. Product Warranty Provisions The Company’s standard policy is to warrant all Niobe Odyssey Vdrive Accrued warranty, which is included in other accrued liabilities, consists of the following: December 31, 2019 December 31, 2018 Warranty accrual, beginning of the fiscal period $ 149,464 $ 164,365 Accrual adjustment for product warranty 56,118 34,253 Payments made (63,885 ) (49,154 ) Warranty accrual, end of the fiscal period $ 141,697 $ 149,464

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	16. Segment Information The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2019 and 2018 were as follows: Year Ended December 31, 2019 2018 United States $ 19,265,635 $ 18,611,676 International 9,636,915 10,734,941 Total $ 28,902,550 $ 29,346,617 All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Valuation And Qualifying Accoun

Valuation And Qualifying Accounts	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation And Qualifying Accounts	SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 Additions Balance at Charged to Beginning of Cost and Balance at the Year Expenses Deductions End of Year Allowance for doubtful accounts and returns: Year ended December 31, 2019 $ 398,847 $ (14,535 ) $ (4,100 ) $ 380,212 Year ended December 31, 2018 $ 361,350 $ 64,294 $ (26,797 ) $ 398,847 Allowance for inventories valuation: Year ended December 31, 2019 $ 4,460,811 $ (351,925 ) $ (213,435 ) $ 3,895,451 Year ended December 31, 2018 $ 3,901,772 $ 320,446 $ 238,593 $ 4,460,811

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2019 or 2018.
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). As of December 31, 2019 and December 31, 2018 the Company did not have any financial assets or liabilities valued at fair value on a recurring basis.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses, freight, handling costs and wasted material attributable to abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred.
Property and Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue and Costs of Revenue	Revenue and Costs of Revenue Revenue Recognition The Company adopted Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates as necessary. Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from system delivery and installation represented 7% and 5% of revenue for the years ended December 31, 2019 and 2018, respectively. Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 33% of revenue for the years ended December 31, 2019 and 2018, respectively. Royalty: The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 10% of revenue for the years ended December 31, 2019 and 2018. Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for one year following installation. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 47% and 52% of revenue for the years ended December 31, 2019 and 2018, respectively. Sublease Revenue: The adoption of new lease accounting guidance as of January 1, 2019 requires the Company to record sublease income as revenue beginning in 2019. Sublease revenue represented 3% of revenue for the year ended December 31, 2019. Year Ended December 31, 2019 2018 Systems $ 2,066,253 $ 1,582,053 Disposables, service and accessories 25,850,174 27,764,564 Sublease 986,123 - Total revenue $ 28,902,550 $ 29,346,617 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $1.1 million as of December 31, 2019. Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract. The following information summarizes the Company’s contract assets and liabilities: December 31, 2019 December 31, 2018 Contract Assets - Unbilled Receivables $ 168,445 $ 251,867 Customer deposits - 487,086 Product shipped, revenue deferred 674,324 645,199 Deferred service and license fees 4,972,389 5,100,402 Total deferred revenue 5,646,713 6,232,687 Less: Long-term deferred revenue (554,258 ) (407,151 ) Total current deferred revenue $ 5,092,455 $ 5,825,536 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2019 and 2018, that was included in the deferred revenue balance at the beginning of each reporting period was $5.6 million and $5.5 million, respectively. The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets, in the Company’s balance sheet was $0.3 million as of December 31, 2019 and December 31, 2018. The Company did not incur any impairment losses during any of the periods presented. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research and Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2019 or 2018 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is re-measured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2019, the Company had 1,857,599 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $2.22 per share, 46,155 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.70 per share, 42,497,068 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock, and 5,610,121 shares of our common stock issuable upon conversion of our Series B Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2019.
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes ,
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. Revenue from Biosense Webster Inc. related to royalties and Odyssey
Reclassifications	Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Effective January 1, 2019, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05. The standard modifies the measurement approach for credit losses on financial instruments, including trade receivables, from an incurred loss method to a current expected credit loss method, otherwise known as “CECL.” The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years; early adoption is permitted. The standard must be adopted by applying a cumulative adjustment to retained earnings. The Company anticipates adopting the standard in the first quarter of 2020, although it does not expect a significant impact to the Company’s financial results. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” as part of its effort to reduce the complexity of accounting standards. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial results.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Revenue Disaggregated by Type	Year Ended December 31, 2019 2018 Systems $ 2,066,253 $ 1,582,053 Disposables, service and accessories 25,850,174 27,764,564 Sublease 986,123 - Total revenue $ 28,902,550 $ 29,346,617
Summary of Contract Assets and Liabilities	The following information summarizes the Company’s contract assets and liabilities: December 31, 2019 December 31, 2018 Contract Assets - Unbilled Receivables $ 168,445 $ 251,867 Customer deposits - 487,086 Product shipped, revenue deferred 674,324 645,199 Deferred service and license fees 4,972,389 5,100,402 Total deferred revenue 5,646,713 6,232,687 Less: Long-term deferred revenue (554,258 ) (407,151 ) Total current deferred revenue $ 5,092,455 $ 5,825,536

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following: December 31, 2019 December 31, 2018 Raw materials $ 3,063,532 $ 2,686,870 Work in process 515,262 2,594 Finished goods 2,164,187 2,963,013 Reserve for obsolescence (3,895,451 ) (4,460,811 ) Total inventory $ 1,847,530 $ 1,191,666

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: December 31, 2019 December 31, 2018 Prepaid expenses $ 640,252 $ 401,972 Prepaid commissions 336,594 304,585 Deposits 712,179 455,508 Total prepaid expenses and other assets 1,689,025 1,162,065 Less: Noncurrent prepaid expenses and other assets (218,103 ) (198,365 ) Total current prepaid expenses and other assets $ 1,470,922 $ 963,700

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following: December 31, 2019 December 31, 2018 Equipment $ 6,485,873 $ 6,739,939 Leasehold improvements 2,338,441 2,684,065 8,824,314 9,424,004 Less: Accumulated depreciation (8,573,871 ) (9,080,311 ) Net property and equipment $ 250,443 $ 343,693

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: December 31, 2019 December 31, 2018 Accrued salaries, bonus, and benefits $ 1,421,150 $ 1,491,844 Accrued licenses and maintenance fees 483,879 577,389 Accrued warranties 141,697 149,464 Accrued taxes 206,232 192,268 Accrued professional services 383,342 489,017 Other 340,321 383,960 Total accrued liabilities 2,976,621 3,283,942 Less: Long term accrued liabilities (255,517 ) (641,461 ) Total current accrued liabilities $ 2,721,104 $ 2,642,481

Lease Obligations (Tables)

Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Lease Costs and Other Lease Information	The following table represents lease costs and other lease information. Year Ended December 31, 2019 Operating lease cost $ 2,342,344 Short-term lease cost 77,185 Sublease income (986,123 ) Total lease cost $ 1,433,406 Cash paid within operating cash flows $ 2,458,606
Schedule of Future Minimum Operating Lease Payments	The future minimum lease payments under non-cancelable leases as of December 31, 2019 are as follows (excluding any potential sublease income): December 31, 2019 2020 $ 2,339,810 2021 2,382,661 2022 and thereafter - Total lease payments $ 4,722,471 Less: Interest (384,745 ) Present value of lease liabilities $ 4,337,726

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Summary of Reserved Shares of Common Stock	The Company has reserved shares of common stock for conversion of convertible preferred stock, exercise of warrants, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: December 31, 2019 December 31, 2018 Warrants 46,155 1,131,151 Series A Convertible Preferred Stock 46,398,904 47,844,562 Series B Convertible Preferred Stock 5,610,121 - Stock award plans 3,216,028 4,438,503 Employee Stock Purchase Plan 261,603 51,251 55,532,811 53,465,467
Summary of Option and Stock Appreciation Rights Activity	A summary of the option and stock appreciation rights activity for the year ended December 31, 2019 is as follows: Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2018 1,165,086 $0.74 - $43.90 $ 2.54 Granted 1,027,000 $2.03 - $4.48 $ 2.12 Exercised (134,313 ) $0.74 - $2.15 $ 1.17 Forfeited (200,174 ) $0.74 - $43.90 $ 4.29 Outstanding, December 31, 2019 1,857,599 $0.74 - $36.20 $ 2.22
Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price	A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Year Ended December 31, 2019 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $0.00 - $1.00 656,444 8.17 $ 0.74 265,366 $ 0.74 $1.01 - $2.00 96,333 6.78 $ 1.50 62,794 $ 1.73 $2.01- $4.00 957,477 8.83 $ 2.05 83,477 $ 2.15 $4.01 - $10.00 117,500 5.94 $ 4.17 82,500 $ 4.04 $10.01 - $20.00 - - $ - - $ - $30.01 - $40.00 29,845 0.91 $ 34.73 29,845 $ 34.73 1,857,599 8.18 $ 2.22 523,982 $ 3.54
Summary of Restricted Stock Unit Activity	A summary of the restricted stock unit activity for the year ended December 31, 2019 is as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2018 647,649 $ 0.83 Granted 420,000 $ 1.98 Vested (207,212 ) $ 1.36 Forfeited (19,725 ) $ 0.74 Outstanding, December 31, 2019 840,712 $ 1.28

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Provision For Income Taxes	The provision for income taxes consists of the following: Year Ended December 31, 2019 2018 Deferred: Federal $ (827,984 ) $ (236,779 ) State and local (41,740 ) (238,946 ) (869,724 ) (475,725 ) Valuation allowance 869,724 475,725 $ — $ —
Schedule of Reconciliation of Federal Income Tax Rate	The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Year Ended December 31, 2019 2018 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.8 % (42.8 )% Permanent differences between book and tax (3.3 )% (390.5 )% Deferred tax adjustments 0.0 % 293.5 % State rate adjustments (0.9 )% (292.9 )% Prior year return-to-provision adjustment 0.3 % 4.3 % Valuation allowance (18.9 )% 407.4 % Effective income tax rate — % — %
Schedule of Components of Deferred Tax Asset	The components of the deferred tax asset are as follows: December 31, 2019 2018 Current accruals $ 1,660,817 $ 1,746,094 Operating lease liabilities 1,021,891 - Deferred revenue 2,749 605 Depreciation and amortization 1,095,119 1,279,973 Deferred compensation 576,269 471,143 Net operating loss carryovers 23,960,965 22,933,668 Deferred tax assets 28,317,810 26,431,483 Valuation allowance (27,228,805 ) (26,359,083 ) Net deferred tax assets before deferred tax liabilities 1,089,005 72,400 Operating lease right-of-use assets (1,009,721 ) — Capitalized compensation costs (79,284 ) (72,400 ) Net deferred tax assets $ — $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Net loss per share attributable to common stockholders:
Schedule of Computation of Basic and Diluted Earnings Per Share	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations: Year Ended December 31, 2019 2018 Net income (loss) $ (4,591,284 ) $ 116,756 Cumulative dividend on convertible preferred stock (1,429,400 ) (1,434,000 ) Net loss attributable to common stockholders $ (6,020,684 ) $ (1,317,244 ) Weighted average number of common shares and equivalents: 63,051,581 52,082,618 Basic EPS $ (0.10 ) $ (0.03 ) Diluted EPS $ (0.10 ) $ (0.03 )
Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share	The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: December 31, 2019 2018 Shares issuable upon vesting/exercise of: Options to purchase common stock 1,857,599 1,165,086 Series A Convertible Preferred Stock and Accumulated Dividends 42,497,068 41,743,654 Series B Convertible Preferred Stock 5,610,121 - Restricted stock units 840,712 647,649 Warrants 46,155 1,131,151 50,851,655 44,687,540

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	12 Months Ended
	Dec. 31, 2019
Product Warranties Disclosures [Abstract]
Schedule of Accrued Warranty	Accrued warranty, which is included in other accrued liabilities, consists of the following: December 31, 2019 December 31, 2018 Warranty accrual, beginning of the fiscal period $ 149,464 $ 164,365 Accrual adjustment for product warranty 56,118 34,253 Payments made (63,885 ) (49,154 ) Warranty accrual, end of the fiscal period $ 141,697 $ 149,464

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of Geographic Revenues	Geographic revenues for the years ended December 31, 2019 and 2018 were as follows: Year Ended December 31, 2019 2018 United States $ 19,265,635 $ 18,611,676 International 9,636,915 10,734,941 Total $ 28,902,550 $ 29,346,617

Description of Business (Detail

Description of Business (Details Narrative)	Dec. 31, 2019Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Installed base	123

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 05, 2018	Jan. 02, 2018
Restricted cash
Effect on accumulated deficit				$ 3,000,000
Remaining performance obligation	1,100,000
Revenue recognized	5,600,000	5,500,000
Capitalized contract acquisition costs	300,000	300,000
Research and development receivables
Potential common shares excluded from diluted earnings per share	50,851,655	44,687,540
Weighted average exercise price	$ 2.22	$ 2.54
Exercise price of warrants	$ 0.70
Revenues	$ 28,902,550	$ 29,346,617
Series A Convertible Preferred Stock [Member]
Potential common shares excluded from diluted earnings per share	42,497,068
Series B Convertible Preferred Stock [Member]
Potential common shares excluded from diluted earnings per share	5,610,121
Warrants [Member]
Potential common shares excluded from diluted earnings per share	46,155
Exercise price of warrants	$ 0.70
Stock Options and Stock Appreciation Rights [Member]
Potential common shares excluded from diluted earnings per share	1,857,599
Weighted average exercise price	$ 2.22
Restricted Stock Units [Member]
Potential common shares excluded from diluted earnings per share
Revenue from System Delivery and Installation [Member]
Revenues percentage	7.00%	5.00%
Disposable Revenue [Member]
Revenues percentage	33.00%	33.00%
Royalty Revenue [Member]
Revenues percentage	10.00%	10.00%
Other Recurring Revenue [Member]
Revenues percentage	47.00%	52.00%
Sublease Revenue [Member]
Revenues percentage	3.00%
Sales Revenue [Member] | Country Other Than U.S. [Member]
Revenues percentage	10.00%	10.00%
Sales Revenue [Member] | Biosense Webster Inc [Member] | Customer Concentration Risk [Member]
Revenues percentage	10.00%	10.00%
Revenues	$ 2,800,000	$ 2,900,000
Sales Revenue [Member] | Customer [Member] | Customer Concentration Risk [Member]
Revenues percentage	10.00%
Minimum [Member]
Property and equipment, estimated useful lives	3 years
Intangible assets, estimated useful lives	10 years
Share-based compensation, requisite service period	1 year
Exercise price of warrants			$ 0.28
Maximum [Member]
Property and equipment, estimated useful lives	10 years
Intangible assets, estimated useful lives	15 years
Share-based compensation, requisite service period	4 years
Exercise price of warrants			$ 0.70

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Revenue Disaggregated by Type (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total revenue	$ 28,902,550	$ 29,346,617
Sublease	986,123
Systems [Member]
Total revenue	2,066,253	1,582,053
Disposables, Service and Accessories [Member]
Total revenue	$ 25,850,174	$ 27,764,564

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Contract Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Contract Assets - Unbilled Receivables	$ 168,445	$ 251,867
Total deferred revenue	5,646,713	6,232,687
Less: Long-term deferred revenue	(554,258)	(407,151)
Total current deferred revenue	5,092,455	5,825,536
Customer Deposits [Member]
Total deferred revenue		487,086
Product Shipped, Revenue Deferred [Member]
Total deferred revenue	674,324	645,199
Deferred Service and License Fees [Member]
Total deferred revenue	$ 4,972,389	$ 5,100,402

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 3,063,532	$ 2,686,870
Work in process	515,262	2,594
Finished goods	2,164,187	2,963,013
Reserve for obsolescence	(3,895,451)	(4,460,811)
Total inventory	$ 1,847,530	$ 1,191,666

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 640,252	$ 401,972
Prepaid commissions	336,594	304,585
Deposits	712,179	455,508
Total prepaid expenses and other assets	1,689,025	1,162,065
Less: Noncurrent prepaid expenses and other assets	(218,103)	(198,365)
Total current prepaid expenses and other assets	$ 1,470,922	$ 963,700

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Gross property and equipment	$ 8,824,314	$ 9,424,004
Less: Accumulated depreciation	(8,573,871)	(9,080,311)
Net property and equipment	250,443	343,693
Equipment [Member]
Gross property and equipment	6,485,873	6,739,939
Leasehold Improvements [Member]
Gross property and equipment	$ 2,338,441	$ 2,684,065

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense		$ 65,988
Impairment charges		$ 93,482

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,421,150	$ 1,491,844
Accrued licenses and maintenance fees	483,879	577,389
Accrued warranties	141,697	149,464
Accrued taxes	206,232	192,268
Accrued professional services	383,342	489,017
Other	340,321	383,960
Total accrued liabilities	2,976,621	3,283,942
Less: Long term accrued liabilities	(255,517)	(641,461)
Total current accrued liabilities	$ 2,721,104	$ 2,642,481

Long-Term Debt and Credit Fac_2

Long-Term Debt and Credit Facilities (Details Narrative) - USD ($)	Jun. 27, 2019	Apr. 26, 2018	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total liquidity			$ 33,800,000
Cash and cash equivalents			30,182,115	$ 10,796,072
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 5,000,000
Line of credit extended date, description	On June 27, 2019, the Company entered into a Second Amendment to and Reinstatement of Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to June 30, 2020 under substantially identical terms to the prior agreement.	On April 26, 2018, the Company entered into a First Amendment to Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank to extend the maturity of the revolving line of credit to April 25, 2019.
Liquidity ratio		Greater than 1.75:1.00
Minimum unrestricted cash balance		$ 1,500,000
Line of credit facility, current borrowing capacity			3,600,000
Revolving Credit Facility [Member] | Prime Rate [Member] | Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate		4.50%
Revolving Credit Facility [Member] | Floor Rate [Member] | Non-Streamline Period [Member]
Debt Instrument [Line Items]
Line of credit interest rate		1.50%
Revolving Credit Facility [Member] | Primary Lender [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 5,000,000
Revolving Credit Facility [Member] | Primary Lender [Member]
Debt Instrument [Line Items]
Line of credit maturity date			Jun. 30, 2020
Revolving Credit Facility [Member] | Primary Lender [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Line of credit interest rate			4.50%

Lease Obligations (Details Narr

Lease Obligations (Details Narrative) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Operating Leased Assets [Line Items]
Weighted average discount rate for operating leases	9.00%
Weighted average remaining lease term for operating lease term	2 years
Right of use assets	$ 4,286,064
Undiscounted future cash flows to be received under the sublease 2020	1,000,000
Undiscounted future cash flows to be received under the sublease 2021	$ 1,000,000
Accounting Standards Update 2016-02 [Member]
Operating Leased Assets [Line Items]
Right of use assets		$ 6,200,000

Lease Obligations - Schedule of

Lease Obligations - Schedule of Lease Costs and Other Lease Information (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease cost	$ 2,342,344
Short-term lease cost	77,185
Sublease income	(986,123)
Total lease cost	1,433,406
Cash paid within operating cash flows	$ 2,458,606

Lease Obligations - Schedule _2

Lease Obligations - Schedule of Future Minimum Operating Lease Payments (Details)	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 2,339,810
2021	2,382,661
2022 and thereafter
Total lease payments	4,722,471
Less: Interest	(384,745)
Present value of lease liabilities	$ 4,337,726

Convertible Preferred Stock a_3

Convertible Preferred Stock and Stockholders' Equity (Details Narrative)	Aug. 07, 2019USD ($)$ / sharesshares	Mar. 05, 2018USD ($)$ / shares	May 31, 2019USD ($)shares	Sep. 30, 2016$ / sharesshares	Jun. 30, 2014USD ($)shares	Dec. 31, 2019USD ($)Integer$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stockholders votes | Integer						1
Dividends declared | $
Dividends paid | $
Common stock, par value						$ 0.001	$ 0.001
Preferred stock, par or stated value						0.001	$ 0.001
Exercise price of warrants						$ 0.70
Warrants exercisable date						Sep. 29, 2021
Proceeds from warrant exercise | $							$ 9,864,697
Increased in common shares outstanding | shares						35,791,927
Increased in stockholders' equity | $						$ 27,000,000
Options and stock appreciation rights outstanding | shares						1,857,599	1,165,086
Total compensation cost not yet recognized | $						$ 1,600,000
Weighted average amortization period of total compensation cost not yet recognized						4 years
Remaining shares available for issuance | shares						55,532,811	53,465,467
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock plan expiration date						Mar. 25, 2012
2012 Stock Incentive Plan [Member] | New Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period						2 years
2012 Stock Incentive Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term						10 years
Exercise price as percentage of fair value						100.00%
Options vesting percentage						25.00%
Options vesting period						3 years
2012 Stock Incentive Plan [Member] | Stock Option [Member] | Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term						10 years
Exercise price as percentage of fair value						100.00%
2012 Stock Incentive Plan [Member] | Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration term						10 years
Options vesting percentage						25.00%
Options vesting period						3 years
2012 Stock Incentive Plan [Member] | Time-Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period						3 years
2012 Stock Incentive Plan [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period						4 years
Share price						$ 5.29
Intrinsic value, outstanding | $						$ 4,400,000
Intrinsic value, vested | $						$ 300,000
2012 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual life						8 years 2 months 5 days
Options and stock appreciation rights outstanding | shares						1,857,599
Vested and exercisable | shares						523,982
Vested and exercisable, weighted average exercise price						$ 3.54
Vested and exercisable, weighted average remaining term						6 years 4 months 6 days
Intrinsic value of option | $						$ 6,600,000	$ 300,000
Share price						$ 5.29	$ 1.08
Number of shares, vested | shares						494,137
Weighted average grant date fair value						$ 2.12	$ 0.76
2009 Employee Stock Purchase Plan ("ESPP") [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares authorized for issuance | shares			250,000		250,000
Eligible employees term			3 months		3 months
Maximum purchase percentage of employees compensation			15.00%		15.00%
Maximum fair value of shares subject to repurchase obligation | $			$ 25,000		$ 25,000
Maximum fair value percentage of shares subject to repurchase obligation			95.00%		95.00%
Remaining shares available for issuance | shares						261,603
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants		$ 0.70
Maximum [Member] | 2012 Stock Incentive Plan [Member] | Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period						5 years
Maximum [Member] | 2012 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value, exercised | $						$ 400,000	$ 100,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants		$ 0.28
Minimum [Member] | 2012 Stock Incentive Plan [Member] | Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period						1 year
Series A Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, par or stated value				$ 1,000
Number of preferred stock issued | shares				24,000
Preferred stock, par value				$ 0.001
Preferred stock, conversion price				$ 0.65
Common stock issuable from warrants | shares				36,923,078
Preferred stock dividend rate				6.00%
Preferred stock redemption, triggering event, percent of common stock sold threshold				50.00%
Remaining shares available for issuance | shares						46,398,904	47,844,562
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants						$ 0.70
Proceeds from warrant exercise | $		$ 10,000,000
Remaining shares available for issuance | shares						46,155	1,131,151
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds received | $	$ 23,100,000
Private Placement [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares sold | shares	6,585,000
Common stock, par value	$ 0.001
Sale of stock, price per share	$ 2.05
Private Placement [Member] | Series B Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares sold | shares	5,610,121
Preferred stock, par or stated value	$ 0.001
Conversion price per share	$ 2.05

Convertible Preferred Stock a_4

Convertible Preferred Stock and Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Reserved shares of common stock	55,532,811	53,465,467
Stock Award Plans [Member]
Class of Stock [Line Items]
Reserved shares of common stock	3,216,028	4,438,503
Employee Stock Purchase Plan ("ESPP") [Member]
Class of Stock [Line Items]
Reserved shares of common stock	261,603	51,251
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock	46,398,904	47,844,562
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock	5,610,121
Warrants [Member]
Class of Stock [Line Items]
Reserved shares of common stock	46,155	1,131,151

Convertible Preferred Stock a_5

Convertible Preferred Stock and Stockholders' Equity - Summary of Option and Stock Appreciation Rights Activity (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options/SARs, Outstanding, Beginning Balance | shares	1,165,086
Number of Options/SARs, Granted | shares	1,027,000
Number of Options/SARs, Exercised | shares	(134,313)
Number of Options/SARs, Forfeited | shares	(200,174)
Number of Options/SARs, Outstanding, Ending Balance | shares	1,857,599
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 2.54
Weighted Average Exercise Price per Share, Granted	2.12
Weighted Average Exercise Price per Share, Exercised	1.17
Weighted Average Exercise Price per Share, Forfeited	4.29
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	2.22
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	43.90
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	2.03
Range of Exercise Price, Upper Limit	4.48
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	2.15
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	43.90
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	$ 36.20

Convertible Preferred Stock a_6

Convertible Preferred Stock and Stockholders' Equity - Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price (Details) - Stock Options and Stock Appreciation Rights (SARs) [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding | shares	1,857,599
Weighted Average Remaining Life	8 years 2 months 5 days
Weighted Average Exercise Price	$ 2.22
Number of Options Currently Exercisable | shares	523,982
Weighted Average Exercise Price per Vested Share	$ 3.54
Range of Exercise Prices One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0
Range of Exercise Price, Upper Limit	$ 1
Options Outstanding | shares	656,444
Weighted Average Remaining Life	8 years 2 months 1 day
Weighted Average Exercise Price	$ 0.74
Number of Options Currently Exercisable | shares	265,366
Weighted Average Exercise Price per Vested Share	$ 0.74
Range of Exercise Prices Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	1.01
Range of Exercise Price, Upper Limit	$ 2
Options Outstanding | shares	96,333
Weighted Average Remaining Life	6 years 9 months 11 days
Weighted Average Exercise Price	$ 1.50
Number of Options Currently Exercisable | shares	62,794
Weighted Average Exercise Price per Vested Share	$ 1.73
Range of Exercise Prices Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	2.01
Range of Exercise Price, Upper Limit	$ 4
Options Outstanding | shares	957,477
Weighted Average Remaining Life	8 years 9 months 29 days
Weighted Average Exercise Price	$ 2.05
Number of Options Currently Exercisable | shares	83,477
Weighted Average Exercise Price per Vested Share	$ 2.15
Range of Exercise Prices Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	4.01
Range of Exercise Price, Upper Limit	$ 10
Options Outstanding | shares	117,500
Weighted Average Remaining Life	5 years 11 months 8 days
Weighted Average Exercise Price	$ 4.17
Number of Options Currently Exercisable | shares	82,500
Weighted Average Exercise Price per Vested Share	$ 4.04
Range of Exercise Prices Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	10.01
Range of Exercise Price, Upper Limit	$ 20
Options Outstanding | shares
Weighted Average Remaining Life	0 years
Weighted Average Exercise Price
Number of Options Currently Exercisable | shares
Weighted Average Exercise Price per Vested Share	$ 0
Range of Exercise Prices Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	30.01
Range of Exercise Price, Upper Limit	$ 40
Options Outstanding | shares	29,845
Weighted Average Remaining Life	10 months 28 days
Weighted Average Exercise Price	$ 34.73
Number of Options Currently Exercisable | shares	29,845
Weighted Average Exercise Price per Vested Share	$ 34.73

Convertible Preferred Stock a_7

Convertible Preferred Stock and Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2018 | shares	647,649
Number of Restricted Stock Units, Granted | shares	420,000
Number of Restricted Stock Units, Vested | shares	(207,212)
Number of Restricted Stock Units, Forfeited | shares	(19,725)
Number of Restricted Stock Units, Outstanding, December 31, 2019 | shares	840,712
Weighted Average Grant Date Fair Value Per Unit, Outstanding, December 31, 2018 | $ / shares	$ 0.83
Weighted Average Grant Date Fair Value Per Unit, Granted | $ / shares	1.98
Weighted Average Grant Date Fair Value Per Unit, Vested | $ / shares	1.36
Weighted Average Grant Date Fair Value Per Unit, Forfeited | $ / shares	0.74
Weighted Average Grant Date Fair Value Per Unit, Outstanding, December 31, 2019 | $ / shares	$ 1.28

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating loss carryforwards	$ 104,800,000
Net operating loss carryovers expiring unused	96,900,000
Reserves for uncertain tax positions	100,000	$ 100,000
Accrued interest and penalties	100,000
Federal [Member]
Net operating loss carryovers expiring unused	$ 279,800,000
Federal [Member] | Minimum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2030
Federal [Member] | Maximum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2037
State [Member]
Net operating loss carryovers expiring unused	$ 2,000,000
Number of prior years subject to examination	10 years
State [Member] | Minimum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2020
State [Member] | Maximum [Member]
Operating loss carryforwards, expiration date	Dec. 31, 2039

Income Taxes - Schedule of Pro

Income Taxes - Schedule of Provision For Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Deferred: Federal	$ (827,984)	$ (236,779)
Deferred: State and local	(41,740)	(238,946)
Total deferred income tax expense (benefit)	(869,724)	(475,725)
Valuation allowance	869,724	475,725
Income tax benefit

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21.00%	21.00%
State and local taxes, net of federal tax benefit	1.80%	(42.80%)
Permanent differences between book and tax	(3.30%)	(390.50%)
Deferred tax adjustments	0.00%	293.50%
State rate adjustments	(0.90%)	(292.90%)
Prior year return-to-provision adjustment	0.30%	4.30%
Valuation allowance	(18.90%)	407.40%
Effective income tax rate	0.00%	0.00%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Asset (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Current accruals	$ 1,660,817	$ 1,746,094
Operating lease liabilities	1,021,891
Deferred revenue	2,749	605
Depreciation and amortization	1,095,119	1,279,973
Deferred compensation	576,269	471,143
Net operating loss carryovers	23,960,965	22,933,668
Deferred tax assets	28,317,810	26,431,483
Valuation allowance	(27,228,805)	(26,359,083)
Net deferred tax assets before deferred tax liabilities	1,089,005	72,400
Operating lease right-of-use assets	(1,009,721)
Capitalized compensation costs	(79,284)	(72,400)
Net deferred tax assets

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic And Diluted Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net loss per share attributable to common stockholders:
Net income (loss)	$ (4,591,284)	$ 116,756
Cumulative dividend on convertible preferred stock	(1,429,400)	(1,434,000)
Net loss attributable to common stockholders	$ (6,020,684)	$ (1,317,244)
Weighted average number of common shares and equivalents:	63,051,581	52,082,618
Basic EPS	$ (0.10)	$ (0.03)
Diluted EPS	$ (0.10)	$ (0.03)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Anti-dilutive common shares excluded from the computation of diluted earnings per share	50,851,655	44,687,540
Options to Purchase Common Stock [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,857,599	1,165,086
Series A Convertible Preferred Stock and Accumulated Dividends [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	42,497,068	41,743,654
Series B Convertible Preferred Stock [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	5,610,121
Restricted Stock Units [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	840,712	647,649
Warrants [Member]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	46,155	1,131,151

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Compensation expense recognized	$ 200,000	$ 200,000
Employer match of employee contributions	3.00%	3.00%

Product Warranty Provisions (De

Product Warranty Provisions (Details Narrative)	12 Months Ended
	Dec. 31, 2019
Product Warranties Disclosures [Abstract]
Standard product warranty coverage term	1 year

Product Warranty Provisions - S

Product Warranty Provisions - Schedule of Accrued Warranty (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Product Warranties Disclosures [Abstract]
Warranty accrual, beginning of the fiscal period	$ 149,464	$ 164,365
Accrual adjustment for product warranty	56,118	34,253
Payments made	(63,885)	(49,154)
Warranty accrual, end of the fiscal period	$ 141,697	$ 149,464

Segment Information (Details Na

Segment Information (Details Narrative)	12 Months Ended
	Dec. 31, 2019Segments
Segment Reporting [Abstract]
Operating segment	1

Segment Information - Schedule

Segment Information - Schedule of Geographic Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total	$ 28,902,550	$ 29,346,617
Operating Segments [Member] | United States [Member]
Total	19,265,635	18,611,676
Operating Segments [Member] | International [Member]
Total	$ 9,636,915	$ 10,734,941

Valuation And Qualifying Acco_2

Valuation And Qualifying Accounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allowance For Doubtful Accounts [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 398,847	$ 361,350
Additions Charged to Cost and Expenses	(14,535)	64,294
Deductions	(4,100)	(26,797)
Balance at the End of Year	380,212	398,847
Inventory Valuation Reserve [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	4,460,811	3,901,772
Additions Charged to Cost and Expenses	(351,925)	320,446
Deductions	(213,435)	238,593
Balance at the End of Year	$ 3,895,451	$ 4,460,811